Contact Us     Privacy Policy     Terms of Use                                                                            © Copyright Pharma CI Conference & Exhibition 2009.  All Rights Reserved.
2009 PROGRAM AGENDA:  Highlighted Program Designed for Medical Device Professionals   
Sheraton Parsippany Hotel, New Jersey
SEPTEMBER 15-16
DAY 1 (Tuesday, September 15, 2009)
General Session:
7:15-8:15
 Registration & Networking Breakfast in Exhibition Hall

__________________________________________________________________________________________________________________________________
8:15-8:30
 Chairpersons’ Opening Remarks

Pharma Co-Chair: Daniel Pascheles, Head, Global Competitive Intelligence, Merck

Pharma Co-Chair: Sue Ward, Director, Competitive Intelligence, Pfizer

Device Co-Chair: David Van Mook, Manager CI, Roche Diagnostics
__________________________________________________________________________________________________________________________________
8:30-9:15
 Who Moved My Cheese? –The Biopharmaceutical Industry Can Adapt To Change For A Brighter Future
A thought provoking and insightful presentation by a biotechnology equity research analyst that will cover multiple facets of the changes – encompassing financial,
regulatory, and reimbursement – occurring in the U.S., and how the industry can be better prepared for these changes.  The presentation will engage a discussion in
how our drug development strategies of the past decade impacts the present, and how the industry can be better positioned for the future.

Biren Amin, Principal, T-Rx Advisers - Soleil Securities Corp.
__________________________________________________________________________________________________________________________________
9:15-10:00
 Follow-on Biologics: Political Landscape and Key Provisions
    1. While the European experience with FOBs has been mixed, odds are better than half that 2009 will be the year for legislation.
    2. The savings FOBs promise are related to term of data exclusivity and threshold for interchangeability.
    3. The FDA possesses all the tools it needs to review and approve FOBs, but will do so slowly.
    4. Merck's announcement of its interest in FOBs implies it perceives a first mover advantage and an economic profit.
    5. FOBs with a greater therapeutic index should be expected and could be priced at a premium rather than a discount.

Gregory Frykman, Senior Vice President, Pharmaceutical and Biotechnology Analyst, Stanford Group Companies

__________________________________________________________________________________________________________________________________
10:00-11:00
 Networking & Refreshments in Exhibition Hall

__________________________________________________________________________________________________________________________________
11:00-12:00
 Keynote Panel: Reaction/Response to Keynote Presentations

Jospeh DeVivo,  Global President, Reconstructive Orthopaedics, Smith & Nephew

Monika Giese, Former Head Global CI, Novartis Pharma AG

Craig McHenry, Senior Director, Competitor Insights, Wyeth

Daniel Pascheles, Vice President, Global Competitive Intelligence, Merck

Jonas Pedersen, Executive Director, Deallus

Dawn Renear, Vice President, Competitive & Technical Information, Genzyme

Marcus Schabacker, Senior Vice President and Chief Scientific Officer, ConvaTec

Sue Ward, Director, Information & Knowledge Management, Pfizer

__________________________________________________________________________________________________________________________________
12:00-12:30
 Managed Markets, Formularies & You: The Use of Competitive Intelligence to Understand the Most Influential
Growth Sales and Marketing Category
This presentation will discuss:
  • The social and cultural paradigm shift and its implications
  • Physician detailing decline and formulary growth: A look at the #’s
  • How and where to re-focus your company’s internal/external CI activities
  • What resources are needed to effectively build a successful MM CI function
  • A model for future MM & formulary CI implementation

Steve Levy, Managing Director, Fletcher/CSI

__________________________________________________________________________________________________________________________________
12:30-2:00
 Keynote: Game Your Way to an Ethical CI Program
In addition to learning the latest findings from Fuld & Company's global CI ethics survey, Mr. Fuld will show you how to practically align your legal and ethical
guidelines by playing a "Scruples"-like game.  In this highly interactive session, you will learn how to:
  • Avoid over-writing your information-gathering guidelines with meaningless, unmemorable rules
  • Identify ethical areas where your firm may have overlooked
  • Have your entire organization learn and apply these guidelines through stories and group gaming


Leonard Fuld, President, Fuld & Company

_________________________________________________________________________________________________
2:00-3:00
 Networking Roundtables/Discussion
(Led by an expert at each table placed throughout exhibition hall. Participants may freely move from one table to another in this open space environment.)
  ROUNDTABLE 1:
 Customized Healthcare in a Comparative Effectiveness World
Wayne Rosenkrans, Distinguished Fellow, MIT Center for Biomedical Innovation
  ROUNDTABLE 2:
 Conducting CI in Emerging Markets
Marjorie Norman, Manager, Competitive Intelligence, Pfizer
  ROUNDTABLE 3:
 Technology Roadmapping
Richard Traxler, Senior Manager of Technology Planning, Boston Scientific
Sarah Audet, Director of Technology Planning, Medtronic
  ROUNDTABLE 4:
 Landscape of Chinese Pharma and Conducting BI/CI in China
James Shen, Publisher, Pharma China
  ROUNDTABLE 5:
 Identifying how CI can best support R&D
Pablo Prados, Head Scientific Competitive Intelligence, Sanofi-Aventis
  ROUNDTABLE 6:
 CMO Trends and Differences Between CMO Intelligence vs. Big Pharma/Biotech
Mary Ann Sarao, Sr. Director, Strategic Business Intelligence, DSM Pharmaceuticals
  ROUNDTABLE 7:
 CI in M&A Strategy
Debbie Allison, Senior Director, Global Corporate Licensing, Merck
  ROUNDTABLE 8:
 Oncology Commercialization Strategies
Chandra Ramanathan, Senior Director, New Business Oncology, Wyeth
  ROUNDTABLE 9:
 How to Effectively Analyze your Competitor’s Clinical Trials
Deborah Dauber, Associate Director Competitive Intelligence, Genentech
  ROUNDTABLE 10:
 Identifying and Assessing Novel Approaches to CI
Friederike Wirtz-Brugger, Associate Director Scientific Competitive Intelligence, Sanofi-Aventis
  ROUNDTABLE 11:
 Developing a Counter-Intelligence System
Christopher Perkins, Head Global Business Intelligence – Diabetes Care, Roche Diagnostics
  ROUNDTABLE 12:
 Optimizing your Time and Resources with an External CI-Support System
Alok Aggarwal, Co-Founder and Chairman, Evalueserve
3:00-4:00
 Networking & Refreshments in Exhibition Hall
4:00-4:40
 TRACK A
 Competitive Intelligence and the Law: Myths and Facts
This presentation explains the legal basis of Competitive Intelligence.  Learn that collecting competitive information on a competitor is not only
legal but also encouraged by the law.  In addition learn how to understand what makes an information collection technique illegal and and how
to recognize the line between law and ethics.  Specific topics to be discussed include what is a “gray zone,” and whether it is legal to overhear a
competitor on an airplane, to pick up a competitor’s lost document in the street, or to misidentify oneself as a student.  The presentation also
explains why abiding by the ethical standard will spare CI professionals and their companies potential legal problems and will explain why the
Economic Espionage Act does not affect CI activities that are practiced in an ethical manner.

Richard Horowitz, Esq, Attorney-at-Law, Richard Horowitz & Associates
  TRACK B
 CI Agencies - Intelligence Providers or Consultants?

Jamie Denison-Pender, Managing Director, CIS Lifesciences
Rakesh Verma, Director, CIS Lifesciences
  TRACK C
 How to Leverage on Web-Based Primary Information to Gain Competitive Intelligence?
This presentation will describe the categories of primary information available on the web (clinical trials, drug approval status, consumer
perception of drugs, emerging players), how they can be monitored automatically and how it may be converted into actionable decisions.

Chris Hote, President, Digimind
  TRACK D
 The Challenge of Getting it Right: Innovation of Medical Device Products in Global Markets

James Down, Vice President and Process Executive/Product Lifecycle Management, BD Diagnostics – Preanalytical Systems
5:20-6:00
 TRACK A
 Benchmarking on a Budget:  Harnessing Internal Resources for Technical Intelligence
Time and money are always at a premium for our Competitive Technical Intelligence group.  This case study will illustrate how we leveraged
resources from internal experts and the world wide CTI team at Boehringer Ingelheim to deliver a vision of the future of pharmaceutical
development to management in record time and without any external budget.  The case study will explore:
  • Understanding clients' needs
  • Tapping internal resources
  • Collaboration tools
  • Identifying information sources
  • Defining the final product

Carolyn Foster, Sr. Associate Director, Technology Assessment, Boehringer Ingelheim
Joanne Mesite, Director, Competitive Intelligence & Pipeline Disclosure, Pfizer
  TRACK B
 Aggregators/integrators of news/business information and using RSS delivery to manager
published information alerts to manage and push customized feeds to user
communities/websites.

Nancy Klein, Competitor News Information, GlaxoSmithKline
  TRACK C
 Business Hotspots and Semantic Filtering: How to Deploy Competitive Intelligence to Reveal
What You Cannot See
Evidence-based competitive intelligence is integral for any company to be properly prepared to meet the dynamic challenges, turbulence and
uncertainty of the evolving healthcare/biopharmaceutical environment. Innovative, high-value competitive intelligence must serve
multidimensional roles. First, it must act as a diagnostic detection tool, like a blood test or MRI that reveals information that cannot be seen, or
may not be seen, for some time to come. Then the intelligence must be synthesized and filtered through a robust semantic layering technique
that prioritizes and brings to light the most important emerging threats and opportunities that, if capitalized upon and/or blunted, will drive the
business competitively. Armed with this insight and foresight, a company can better manage its assets and lifecycle plans, allocate its resources
for ROI, and build value for all stakeholders throughout the healthcare chain.

Carl B. Derenfeld, Proactive Worldwide, Vice President, Strategic Solutions – Healthcare
  TRACK D
 Integrating Competitive Intelligence: The Key Ingredient
  • A New Paradigm for Integrating CI, IP, and Licensing
  • On shore/off shore model – the best of both worlds
  • Dealing with CI emergencies – expedited services

Dr. Vimal Mehta, Chairman and Co-founder, Bioxcel Corporation
DAY 2: (Wednesday, September 16, 2009)
7:15-8:15
 Registration & Networking Breakfast in Exhibition Hall

_________________________________________________________________________________________________________________________________
8:15-8:20
 Chairpersons’ Opening Remarks
8:20-9:15
 TRACK A
 How to Best Recruit, Reward, Recognize and Promote CI Professionals Relative to the Rest of the
Organization.

TBA, Bayer HealthCare LLC

Deborah Dauber, Associate Director, Competitive Intelligence, Genentech

Sandipa Dublish, Director Global Market Research, Eisai

JJ Owen, Senior Director, Scientific & Competitor Analysis, Millennium Pharmaceuticals
  TRACK B
 Generics Panel Discussion
Ageing populations, growing importance of emerging markets and rapidly rising treatment costs are causing governments and pharmaceutical
companies throughout the world to look closely at the sustainability of their healthcare provision and business models. Economically priced
generic medicines provide one the means of managing the budget for pharmaceuticals, meet some of the immediate need of emerging markets
and provide opportunities for diversification for Big pharma.  In the recent years a strong trend is observed for accelerated development and
commercialization of generic pharmaceutical products. This would seriously impact the pharmaceutical companies' ability to recoup their costs
and reinvest in other research projects. What needs to be done? What can be done? What should be done first?

The Competitive intelligence professionals can benefit from this discussion to better understand the new trends related to the use and
commercialization of generic products worldwide and get insights how to enhance competitive position of their companies in the global
pharmaceuticals marketplace.

Moderator:
Branimir Brankov, Sr. Director Strategic Business Intelligence, Merck

Panelists:
Neil Mahoney, CEO , Global Pharma Alliance LLC

Cliff Kalb, CEO , C. Kalb & Associates, LLC

Stan Bernard, President, Bernard Associates, LLC

Teva Panelist TBA

Sandoz Panelist TBA
  TRACKC
 Panel of CI Consultants and CI Practitioners to Discuss How Both Sides See Primary Intelligence
Projects Being Most Successful

Michelle Castillo, Director of Competitive Intelligence, Baxter Corporation

Robert Franc, Director of Competitive Intelligence, Lifescan

Steve Levy, Managing Director, Fletcher/CSI

Marjorie Norman, Manager, Information & Knowledge Management, Pfizer

Friederike Wirtz-Brugger, Associate Director, Scientific Competitive Intelligence, Sanofi-Aventis
9:15-10:05
 TRACK A
 Offshoring/ Outsourcing CI:
  • Benefits
  • Pitfalls
  • Can You Outsource CI Completely?  

Beth Autin, Manager, Library Services and Information Management, Gen-Probe

Craig McHenry, Senior Director, Competitor Insights, Wyeth

Raj Dave, Head U.S. Operations, PharmARC Analytic Solutions
  TRACK B
(9:15-9:35)
 Summary of Findings from Pre-Conference Workshop:
Justifying the BI and CI functions using ROI and Other Measurement Tools

Neil Mahoney, President, Global Pharma Alliance
  TRACK B
(9:35-10:05)
 Monitoring Promotional Strategies and Tactics on the Web-
Review e-marketing/promotional strategies including online advertising, e-detailing and other e-communications.  Discuss how they can be
monitored most efficiently and what CI can be mined from them including messaging, scope, target audience.

Salvador Carlucci  (invited), Senior Manager/CI , Novartis AG
  TRACK C
 Patent Research/ M&A Analysis/ Technological Trends in Devices and Diagnostics

Sarah Audet, Director of Technology Planning, Medtronic

Jeff Beeny, Senior Manager of Business Intelligence, Thermo Fisher Scientific

Richard Traxler, Senior Manager of Technology Planning, Boston Scientific
6:00-9:00
 Evening Socializing Events! Casino Gaming, Reception & Networking
11:00-12:00
 TRACK A
 The Strategic Impact of CI on Business Development, Business Growth and Innovation

Debbie Allison, Senior Director, Global Corporate Licensing, Merck

Christopher Perkins, Head Global Business Intelligence – Diabetes Care, Roche Diagnostics

Pablo Prados, Senior Director Scientific Competitive Intelligence, Sanofi-Aventis

Sanjiv Sharma, Vice President of Commercial Affairs, Nicox

Raghu Viswanath, CI Manager, Genzyme
  TRACK B
 Key Elements of Competitive Strategy to Ensure R&D and Commercial Success
Analyzing Pipelines; Product Launches; New Product Planning

Moderator:
Thomas Han, Senior Director, Strategic Marketing, Business Analysis, Biovail

Panelists:
Paul Korathu, Assistant Director, New Product Commercial Analysis,  Astellas Pharma US, Inc.

Valerie Pajak, Senior Manager, Business Intelligence & Analytics, APP Pharmaceuticals

Chandra Ramanathan, Senior Director, New Business Oncology, Wyeth

Shefali Shah, Director of Market Analytics, Exelixis
  TRACK C
 Gaps in the Diagnostics/Device Information Landscape
  • Pharma has a long list of specialized information resources
  • Are there any similar ones in development for Diagnostics/Medical Devices
  • What are the informational resources for this group?

Beth Autin, Manager, Library Services and Information Management, Gen-Probe

Nikki Gainey,   Director of Global Business Analysis, General Electric        

Kim Szymanowski, Competitive Intelligence Manager, Ethicon, a Johnson & Johnson Company        

Wendy Ye,  Principal Competitive Intelligence Specialist, Medtronic
10:05-11:00
 Networking & Refreshments in Exhibition Hall
12:00-12:45
 TRACK A
 Outsourcing All or Part of Your Firm’s C.I. Needs to a Vendor

David Hitchcoff
Vice President, Consulting Services
The Dunn Group, Inc.
  TRACK B
 Unlocking the Wealth in Abandoned Molecules: A Systematic CI-driven Approach
These are exciting times for the pharmaceutical industry. In this "post-blockbuster" age of drug development, there are two concurrent trends in
the industry that create new opportunities:
  • Each company is focusing on a handful of therapeutic areas and exiting from other therapeutic areas, resulting in "orphaned" and
    "abandoned" molecules.
  • Many companies are targeting smaller subpopulations in several therapeutic areas based on the latest scientific understanding.
Some of the abandoned molecules can perhaps be used for targeting new subpopulations. The accumulated knowledge (clinical trials,
toxicology analysis etc.) of the abandoned molecules can help bring them to the market very quickly.  A combination of scientific, market and
patent intelligence can help unlock very valuable opportunities.

Samir Raiyani, CEO, Dolcera
  TRACK C
 Device and Drug Delivery: The Integration and Selection Process
This panel discussion will bring together leaders in the drug delivery device market with leaders in the drug development market to discuss how
alliances can bring sustainable competitive advantage to both groups and the role CI has in the selection of a partner. Panel members will bring
their real-world experience to the presentation and explore how CI has supported the development of partnerships from the early stages of
recognizing when a partner was needed to the late stages of marketing the end product and system.

Attendees will benefit from this unique insight with a better picture of how to assess device and drug company partnerships and how to build
similar partnerships within their own entities.

Moderator:
Erik Glitman, Managing Director, Fletcher/CSI

Panelists TBA
12:45-1:45
 Networking Luncheon

_________________________________________________________________________________________________________________________________
1:45-2:30
 Keynote: CI Managers – Responsible for What Exactly?  

  • CI proving value
  • CI supporting the strategy development process
  • CI finding a "Home" in the organisation.
The presentation includes feedback from a very recent questionnaire to 50 CI Managers in the bio-pharmaceutival industry.

Richard Withers, CEO, Deallus Group

_________________________________________________________________________________________________
2:30-3:15
 Networking Luncheon Presentation:
How CI Can Survive and Thrive In Turbulent Times
Turbulent economic times create new opportunities and threats for CI and BI professionals. This presentation will share field research findings regarding traumatic
changes under way in the global bio-pharma and medical device sectors – with case examples illuminating how savvy CI and BI pros survive and thrive by aligning
organizational intelligence with rapidly changing leadership teams, organizational structures, business units, brands and priorities.

Chris Bogan, CEO, Best Practices

_________________________________________________________________________________________________________________________________
3:15-3:45
 Networking & Refreshments in Exhibition Hall

_________________________________________________________________________________________________________________________________
3:45-4:45
 Keynote: Biosimilars Panel Discussion
The key patents for the first wave of broadly utilized biopharmaceuticals in the major pharmaceutical markets have either expired or are about to expire. The
pharmaceutical market is preparing for biosimilar, biogeneric or biobetter versions of existing biopharmaceuticals. This is presenting a new kind of challenges for
pharma industry, regulatory authorities and patients when compared with the management and utilization of the conventional generics products.  The Competitive
intelligence professionals can benefit from this discussion to better understand the key issues related to the use of these products and get insights necessary to
support strategic and tactical decisions within their registrations.

Moderator:
Branimir Brankov, Sr. Director Strategic Business Intelligence, Merck

Panelists:
E.B. Brakewood, Exec. Director , Merck Bioventures

Richard DiCicco, CEO , Harvest Moon Pharmaceuticals

Frank P. Sama, Senior Manager, Genzyme Corporation

Mary Ann Sarao, Sr. Director Strategic Business Intelligence, DSM Pharmaceuticals

_________________________________________________________________________________________________________________________________
4:45-5:45
 Keynote Panel
Responding to Keynotes and Summarizing Conference Findings/ Key Takeaways

Monika Giese, Former Head Global CI, Novartis Pharma AG

Craig McHenry, Senior Director, Competitor Insights, Wyeth

Daniel Pascheles, Vice President, Global Competitive Intelligence, Merck

Dawn Renear, Vice President, Competitive & Technical Information, Genzyme

David Stefanoni, Director, Business Intelligence; Business Excellent, Analytics & Planning, Sanofi-Aventis

David Van Mook, Manager, CI, Roche Diagnostics

Sue Ward, Director, Competitive Intelligence, Pfizer

_________________________________________________________________________________________________________________________________
5:45
 Conference Concludes
Participants may choose 1 of 4 concurrent tracks
Participants may choose 1 of 4 concurrent tracks
Participants may choose 1 of 3 concurrent tracks
Participants may choose 1 of 3 concurrent tracks
Participants may choose 1 of 3 concurrent tracks
Participants may choose 1 of 3 concurrent tracks
4:40-5:20
 TRACK A
 Social Media Impact On The CI Landscape
This presentation will explore the rapid changes brought by the increasing adoption of social media technologies and what it means to the
information businesses are publishing and collecting. We will first define social media (also known as consumer-generated media) and how it
modifies the way we interact with information. We will review a case study illustrating the impact and effect of social media. Finally, we will
outline a few strategies on how to derive effective information from consumer-generated media.

Jean-Remy Behaeghel, Director, Clinical and Regulatory Solutions, Vertex
  TRACK B
 Effects of the Economic Downturn on Pharma CI / BI Operations:
Results from the Annual CI/BI Professional Survey
The topic of the 2009 annual survey was "Differentiating Intelligence in the Economic Downturn". In essence, we surveyed our Pharma
colleagues to get a better understanding of what the impact of the current downturn has had on intelligence units in our space.  Fifteen units
completed the survey. Results were mixed. Although most companies had experienced some negative effects on overall company performance,
resources dedicated to intelligence operations were up in some units and down in
others. This presentation will review the results of the survey and discuss its implications to the future of activities of CI/BI departments.

Mark Little, Vice President, Business Intelligence & Market Research, Covance
  TRACK C
 Delivering Actionable CI on a Shoe String Budget
In the tough economic times we live in today, the need to deliver actionable intelligence on tighter budgets is a reality for everyone. Gone are
the days of unlimited budgets and resources. This session will address the following issues facing lifesciences CI professionals:
  • What is actionable CI?
  • How do we deliver actionable CI on a Shoe String budget?
  • What are the practical lessons and common pitfalls to avoid?

Arjan Singh, VP, Consulting, Fuld & Co
  TRACK D
 Leveraging CI to Optimize Late Lifecycle Strategic Planning
  • Generic industry overview
  • Strategic options for patent loss
  • Uncertainty in patent loss strategic planning
  • Applying CI to reduce uncertainty
  • Designing an effective generics sector CI project
  • Establishing the value of CI
  • Key take-aways

David Kuczenski, Director of Strategic Market Intelligence, Lifescience Dynamics
Participants may choose 1 of 4 concurrent tracks